Sumitomo Mitsui Trust Group
NTLA icon

Sumitomo Mitsui Trust Group’s Intellia Therapeutics NTLA Stock Holding History

Sumitomo Mitsui Trust Group’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25.3M Sell
1,973,061
-219,400
-10% -$2.79M 0.02% 591
2025
Q4 		$19.7M Sell
2,192,461
-162,395
-7% -$2.24M 0.01% 639
2025
Q3 		$40.7M Sell
2,354,856
-316,409
-12% -$3.9M 0.02% 523
2025
Q2 		$25.1M Sell
2,671,265
-154,096
-5% -$1.27M 0.02% 613
2025
Q1 		$20.1M Sell
2,825,361
-167,302
-6% -$1.69M 0.01% 638
2024
Q4 		$34.9M Sell
2,992,663
-156,736
-5% -$2.45M 0.02% 543
2024
Q3 		$64.7M Sell
3,149,399
-108,290
-3% -$2.5M 0.04% 385
2024
Q2 		$72.9M Sell
3,257,689
-141,629
-4% -$3.37M 0.05% 344
2024
Q1 		$93.5M Sell
3,399,318
-79,244
-2% -$2.2M 0.06% 316
2023
Q4 		$106M Sell
3,478,562
-41,733
-1% -$1.2M 0.08% 269
2023
Q3 		$111M Buy
3,520,295
+125,639
+4% +$4.87M 0.09% 228
2023
Q2 		$138M Buy
3,394,656
+281,692
+9% +$11.4M 0.11% 190
2023
Q1 		$116M Buy
3,112,964
+136,962
+5% +$5.37M 0.09% 253
2022
Q4 		$104M Buy
2,976,002
+12,074
+0.4% +$574K 0.08% 280
2022
Q3 		$166M Buy
2,963,928
+182,792
+7% +$11.3M 0.14% 169
2022
Q2 		$144M Sell
2,781,136
-91,133
-3% -$4.63M 0.11% 207
2022
Q1 		$209M Buy
2,872,269
+118,366
+4% +$10M 0.14% 154
2021
Q4 		$326M Buy
2,753,903
+353,970
+15% +$44.3M 0.2% 112
2021
Q3 		$322M Sell
2,399,933
-727,670
-23% -$110M 0.2% 109
2021
Q2 		$506M Sell
3,127,603
-1,679,691
-35% -$131M 0.3% 74
2021
Q1 		$386M Sell
4,807,294
-297,068
-6% -$19.9M 0.24% 90
2020
Q4 		$278M Sell
5,104,362
-958,154
-16% -$34.8M 0.18% 128
2020
Q3 		$121M Sell
6,062,516
-132,673
-2% -$2.77M 0.08% 261
2020
Q2 		$130M Sell
6,195,189
-896,074
-13% -$15.2M 0.09% 234
2020
Q1 		$86.7M Sell
7,091,263
-87,257
-1% -$1.18M 0.07% 287
2019
Q4 		$105M Sell
7,178,520
-61,217
-0.8% -$852K 0.08% 255
2019
Q3 		$96.7M Buy
7,239,737
+5,023,077
+227% +$80.1M 0.08% 256
2019
Q2 		$36.3M Buy
2,216,660
+1,169,968
+112% +$18.4M 0.03% 533
2019
Q1 		$17.9M Buy
+1,046,692
New +$15.6M 0.02% 650

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Sumitomo Mitsui Trust Group's NTLA Position: Q1 2026 in Review

Sumitomo Mitsui Trust Group reduced its Intellia Therapeutics (NTLA) stake by 10% in Q1 2026, selling an estimated $2.79M and leaving 1,973,061 shares worth $25.3M. The position accounts for 0.02% of the portfolio, ranked #591.

Sumitomo Mitsui Trust Group first reported a position in NTLA in Q1 2019 and has held it in 29 quarters since. The position peaked at $506M in Q2 2021. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Sumitomo Mitsui Trust Group held 1,973,061 shares of Intellia Therapeutics worth $25.3M as of Q1 2026.
  • Sumitomo Mitsui Trust Group sold 219,400 Intellia Therapeutics shares in Q1 2026, an estimated $2.79M.
  • Intellia Therapeutics made up 0.02% of Sumitomo Mitsui Trust Group's portfolio in Q1 2026, its #591 holding.
  • Sumitomo Mitsui Trust Group first reported a position in Intellia Therapeutics in Q1 2019 and has held it in 29 quarters since.
  • Sumitomo Mitsui Trust Group's Intellia Therapeutics position peaked at $506M in Q2 2021.
  • 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Sumitomo Mitsui Trust Group's 13F filing for Q1 2026, filed 30 Apr 2026.